Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States.

Hiligsmann M, Silverman SS, Singer AJ, Pearman L, Mathew J, Wang Y, Caminis J, Reginster JY

PharmacoEconomics22 Apr 2023Cited by 11 (Europe PMC)

PMID37086385PMCIDPMC10232643DOI10.1007/s40273-023-01270-xPepBankPUB-37086385

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

01Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther
In a model of high-risk US men, sequential abaloparatide/alendronate produced more QALYs than sequential unbranded teriparatide/alendronate.
In plain wordsComputer predictions gave sequential abaloparatide/alendronate more quality-adjusted life-years than sequential unbranded teriparatide/alendronate.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseQuality-adjusted life-years
Study
n: not reported in source
Markov microsimulation of US men at high fracture risk
Comparator
Sequential unbranded teriparatide/alendronate
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Over the full age range, sequential ABL/ALN led to more QALYs for lower costs than sequential unbranded TPTD/ALN,
2 context sentences(design, population, supporting numbers)
Summary · context
A Markov-based microsimulation model based on a lifetime US healthcare decision maker perspective was developed to evaluate the cost (expressed in US$2021) per quality-adjusted life-years (QALYs) gained of sequential ABL/ALN.
Summary · context
Analyses were conducted in high-risk men aged over 50 years defined as having a bone mineral density T-score ≤-2.5 and a recent fracture.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3708638501
02Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther
In a model of high-risk US men, sequential abaloparatide/alendronate cost less than sequential unbranded teriparatide/alendronate.
In plain wordsComputer predictions gave sequential abaloparatide/alendronate lower costs than sequential unbranded teriparatide/alendronate.
Peptide
Abaloparatide (Tymlos)
Outcome
DecreaseTreatment costs
Study
n: not reported in source
Markov microsimulation of US men at high fracture risk
Comparator
Sequential unbranded teriparatide/alendronate
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Over the full age range, sequential ABL/ALN led to more QALYs for lower costs than sequential unbranded TPTD/ALN,
2 context sentences(design, population, supporting numbers)
Summary · context
A Markov-based microsimulation model based on a lifetime US healthcare decision maker perspective was developed to evaluate the cost (expressed in US$2021) per quality-adjusted life-years (QALYs) gained of sequential ABL/ALN.
Summary · context
Analyses were conducted in high-risk men aged over 50 years defined as having a bone mineral density T-score ≤-2.5 and a recent fracture.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3708638502
03Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther
In a model of high-risk US men, sequential abaloparatide/alendronate cost per QALY gained was below US$150,000 versus generic alendronate.
In plain wordsComputer predictions placed sequential abaloparatide/alendronate below US$150,000 per quality-adjusted life-year gained versus generic alendronate.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableCost per QALY gained
Study
n: not reported in source
Markov microsimulation of US men at high fracture risk
Comparator
Generic alendronate monotherapy
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
The costs per QALY gained of sequential ABL/ALN were lower than the US threshold of US$150,000 versus generic ALN monotherapy.
2 context sentences(design, population, supporting numbers)
Summary · context
A Markov-based microsimulation model based on a lifetime US healthcare decision maker perspective was developed to evaluate the cost (expressed in US$2021) per quality-adjusted life-years (QALYs) gained of sequential ABL/ALN.
Summary · context
Analyses were conducted in high-risk men aged over 50 years defined as having a bone mineral density T-score ≤-2.5 and a recent fracture.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3708638503
04Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther
In modeled men aged 50 years, sequential abaloparatide/alendronate had a 51% probability of cost effectiveness versus alendronate monotherapy.
In plain wordsComputer predictions at age 50 gave sequential abaloparatide/alendronate a 51% chance of cost effectiveness versus alendronate alone.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableCost-effectiveness probability at age 50
Study
n: not reported in source
Markov microsimulation of US men at high fracture risk
Comparator
Alendronate monotherapy
Outcome group
Cost-effectiveness · Whole body
Measurements
Cost-effectiveness probability
51%
men aged 50 years
Source sentences
Summary
The probabilities that sequential ABL/ALN was cost effective compared to ALN monotherapy were estimated at 51% in men aged 50 years and between 88 and 90% in those aged ≥ 60 years.
2 context sentences(design, population, supporting numbers)
Summary · context
A Markov-based microsimulation model based on a lifetime US healthcare decision maker perspective was developed to evaluate the cost (expressed in US$2021) per quality-adjusted life-years (QALYs) gained of sequential ABL/ALN.
Summary · context
Analyses were conducted in high-risk men aged over 50 years defined as having a bone mineral density T-score ≤-2.5 and a recent fracture.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3708638504
05Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther
In modeled men aged at least 60 years, sequential abaloparatide/alendronate had an 88-90% probability of cost effectiveness versus alendronate monotherapy.
In plain wordsComputer predictions at ages ≥60 gave sequential abaloparatide/alendronate an 88-90% chance of cost effectiveness versus alendronate alone.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableCost-effectiveness probability at age 60 or older
Study
n: not reported in source
Markov microsimulation of US men at high fracture risk
Comparator
Alendronate monotherapy
Outcome group
Cost-effectiveness · Whole body
Measurements
Cost-effectiveness probability
88 to 90%
men aged ≥60 years
Source sentences
Summary
The probabilities that sequential ABL/ALN was cost effective compared to ALN monotherapy were estimated at 51% in men aged 50 years and between 88 and 90% in those aged ≥ 60 years.
2 context sentences(design, population, supporting numbers)
Summary · context
A Markov-based microsimulation model based on a lifetime US healthcare decision maker perspective was developed to evaluate the cost (expressed in US$2021) per quality-adjusted life-years (QALYs) gained of sequential ABL/ALN.
Summary · context
Analyses were conducted in high-risk men aged over 50 years defined as having a bone mineral density T-score ≤-2.5 and a recent fracture.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3708638505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.